Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

This study has been terminated.
Sponsor:
Collaborators:
Ministry of Health, France
Novartis
Information provided by:
Poitiers University Hospital
ClinicalTrials.gov Identifier:
NCT00219765
First received: September 13, 2005
Last updated: November 25, 2005
Last verified: September 2005